bullish
Acorda Therapeutics: Attacking 'OFF' Symptoms in Parkinson's Disease
231 Views22 Nov 2016 11:23
We added Acorda Therapeutics Inc (ACOR US) to our U.S. model portfolio (biotech/pharma) on 7/7/2016 with a price target of $51. Today, the...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Solvency Risk Short Candidates: Invitae, AMC, 2U Inc., Delek US09 Mar 2022
- Invitae: An Emerging Genetic Testing Company with Insider and Institutional Buying25 Nov 2016
- Acorda Therapeutics: Attacking 'OFF' Symptoms in Parkinson's Disease22 Nov 2016
- Long Position with Upcoming Catalysts18 Nov 2016
x